Literature DB >> 11910210

Continuous intrathecal clonidine administration for the treatment of neuropathic pain.

E I Uhle1, R Becker, S Gatscher, H Bertalanffy.   

Abstract

In many cases, the treatment of neuropathic pain by intrathecal opioids fails to meet expectations. In a trial involving 10 patients, the intrathecal administration of clonidine combined with opioids in the treatment of chronic pain was introduced in our department for the first time. Eight patients with neuropathic pain syndromes were subjected to a continuous intrathecal clonidine application in addition to intrathecal morphine. At an average dose of 44 microg clonidine/day, a 70-100% reduction in pain was achieved. Residual non-neuropathic pain in 4 of 8 patients was successfully treated with clonidine and low doses of opioids. On the basis of the results achieved so far, we recommend that clonidine should be routinely tested for intrathecal drug administration, especially in patients with a prominent neuropathic pain component. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11910210     DOI: 10.1159/000048402

Source DB:  PubMed          Journal:  Stereotact Funct Neurosurg        ISSN: 1011-6125            Impact factor:   1.875


  9 in total

1.  [Withdrawal in a patient with an implantable drug delivery system in spite of continuation of opiate therapy].

Authors:  S Lochner; U Heinrich-Gräfe; W Kirch
Journal:  Internist (Berl)       Date:  2010-05       Impact factor: 0.743

Review 2.  A systematic review of pharmacologic treatments of pain after spinal cord injury.

Authors:  Robert W Teasell; Swati Mehta; Jo-Anne L Aubut; Brianne Foulon; Dalton L Wolfe; Jane T C Hsieh; Andrea F Townson; Christine Short
Journal:  Arch Phys Med Rehabil       Date:  2010-05       Impact factor: 3.966

Review 3.  Neuraxial drug administration: a review of treatment options for anaesthesia and analgesia.

Authors:  Stephan A Schug; David Saunders; Irina Kurowski; Michael J Paech
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

4.  Ongoing pain in the MIA model of osteoarthritis.

Authors:  Ping Liu; Alec Okun; Jiyang Ren; Rui-chen Guo; Michael H Ossipov; Jennifer Xie; Tamara King; Frank Porreca
Journal:  Neurosci Lett       Date:  2011-01-15       Impact factor: 3.046

5.  Pharmacologic therapies of pain in patients with spinal cord injury: a systematic review.

Authors:  Mohammad Hossein Asgardoon; Seyed Behnam Jazayeri; Atefeh Behkar; Mohammad Amin Dabbagh Ohadi; Hossein Yarmohammadi; Zahra Ghodsi; Tommaso Ivan Pomerani; Mojtaba Mojtahedzadeh; Vafa Rahimi-Movaghar
Journal:  Spinal Cord Ser Cases       Date:  2022-07-04

6.  Management of Neuropathic Pain Associated with Spinal Cord Injury.

Authors:  Ellen M Hagen; Tiina Rekand
Journal:  Pain Ther       Date:  2015-03-06

7.  Spinal cord stimulation modulates supraspinal centers of the descending antinociceptive system in rats with unilateral spinal nerve injury.

Authors:  Toshiharu Tazawa; Yoshinori Kamiya; Ayako Kobayashi; Kensuke Saeki; Masahito Takiguchi; Yusuke Nakahashi; Hironobu Shinbori; Kengo Funakoshi; Takahisa Goto
Journal:  Mol Pain       Date:  2015-06-24       Impact factor: 3.395

8.  Morphine and clonidine combination therapy improves therapeutic window in mice: synergy in antinociceptive but not in sedative or cardiovascular effects.

Authors:  Laura S Stone; Jonathan P German; Kelly F Kitto; Carolyn A Fairbanks; George L Wilcox
Journal:  PLoS One       Date:  2014-10-09       Impact factor: 3.240

Review 9.  Malformations of the craniocervical junction (Chiari type I and syringomyelia: classification, diagnosis and treatment).

Authors:  Alfredo Avellaneda Fernández; Alberto Isla Guerrero; Maravillas Izquierdo Martínez; María Eugenia Amado Vázquez; Javier Barrón Fernández; Ester Chesa i Octavio; Javier De la Cruz Labrado; Mercedes Escribano Silva; Marta Fernández de Gamboa Fernández de Araoz; Rocío García-Ramos; Miguel García Ribes; Carmen Gómez; Joaquín Insausti Valdivia; Ramón Navarro Valbuena; José R Ramón
Journal:  BMC Musculoskelet Disord       Date:  2009-12-17       Impact factor: 2.362

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.